91 related articles for article (PubMed ID: 9329630)
1. Cytotoxic effect of immunoconjugate composed of glucose-oxidase coupled to an anti-ganglioside (GD2) antibody on spheroids.
Heiss P; Bernatz S; Bruchelt G; Senekowitsch-Schmidtke R
Anticancer Res; 1997; 17(4B):3177-8. PubMed ID: 9329630
[TBL] [Abstract][Full Text] [Related]
2. Distribution of disialoganglioside GD2-antigen and binding of anti-GD2 antibodies on spheroids of neuroblastoma cell line.
Heiss P; Bermatz S; Wehnes H; Heinzmann U; Senekowitsch-Schmidtke R
Anticancer Res; 1997; 17(4B):3145-7. PubMed ID: 9329622
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
4. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
5. Ascorbic acid induces lipid peroxidation on neuroectodermal SK-N-LO cells with high endogenous ferritin content and loaded with MAb-ferritin immunoconjugates.
Lode HN; Bruchelt G; Zinsser D; Baader SL; Rieth AG; Schade UF; Niethammer D
Anticancer Res; 1994; 14(5A):1903-6. PubMed ID: 7847824
[TBL] [Abstract][Full Text] [Related]
6. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
Cheung NK; Modak S
Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity of L-cycloserine against human neuroblastoma and medulloblastoma cells is associated with the suppression of ganglioside expression.
Cinatl J; Cinatl J; Kotchetkov R; Pouckova P; Vogel JU; Rabenau H; Michaelis M; Kornhuber B
Anticancer Res; 1999; 19(6B):5349-54. PubMed ID: 10697560
[TBL] [Abstract][Full Text] [Related]
8. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
[TBL] [Abstract][Full Text] [Related]
9. In vitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody.
Wang CH; Huang YJ; Chang CW; Hsu WM; Peng CA
Nanotechnology; 2009 Aug; 20(31):315101. PubMed ID: 19597244
[TBL] [Abstract][Full Text] [Related]
10. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Clin Cancer Res; 1998 Sep; 4(9):2135-9. PubMed ID: 9748131
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
[TBL] [Abstract][Full Text] [Related]
12. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
[TBL] [Abstract][Full Text] [Related]
13. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
[TBL] [Abstract][Full Text] [Related]
14. Selection of novel peptide mimics of the GD2 ganglioside from a constrained phage-displayed peptide library.
Horwacik I; Czaplicki D; Talarek K; Kowalczyk A; Bolesta E; Kozbor D; Rokita H
Int J Mol Med; 2007 May; 19(5):829-39. PubMed ID: 17390090
[TBL] [Abstract][Full Text] [Related]
15. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.
Miederer M; McDevitt MR; Borchardt P; Bergman I; Kramer K; Cheung NK; Scheinberg DA
Clin Cancer Res; 2004 Oct; 10(20):6985-92. PubMed ID: 15501978
[TBL] [Abstract][Full Text] [Related]
16. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with GD2 specific monoclonal antibodies.
Cheung NK; Medof ME; Munn D
Prog Clin Biol Res; 1988; 271():619-32. PubMed ID: 3043454
[No Abstract] [Full Text] [Related]
18. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma.
Otto M; Barfield RC; Martin WJ; Iyengar R; Leung W; Leimig T; Chaleff S; Gillies SD; Handgretinger R
Clin Cancer Res; 2005 Dec; 11(23):8486-91. PubMed ID: 16322312
[TBL] [Abstract][Full Text] [Related]
19. GD3 ganglioside antibody augments tumoricidal capacity of canine blood mononuclear cells by induction of interleukin 12.
Helfand SC; Dickerson EB; Munson KL; Padilla ML
Cancer Res; 1999 Jul; 59(13):3119-27. PubMed ID: 10397254
[TBL] [Abstract][Full Text] [Related]
20. Disialoganglioside directed immunotherapy of neuroblastoma.
Modak S; Cheung NK
Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
